Evidence map›Paper›PMID 27793166›Full record

Trial reportVirology journal2016

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.

Song Yang, Huichun Xing, Yuming Wang, Jinlin Hou, Duande Luo, Qing Xie, Qin Ning, Hong Ren, Huiguo Ding, Jifang Sheng and 20 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Virology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B.Journal of clinical and translational hepatology · 2018
    Article
  6. [Consensus on pegylated interferon alpha in treatment of chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Song YangCenter of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Huichun XingCenter of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Yuming WangSouthwest Hospital Affiliated Third Military Medical University, Shapingba, Chongqing, 400038, China.
Jinlin HouGuangzhou Nanfang Hospital, Guangzhou, 510515, China.
Duande LuoXiehe Hospital Affiliated Tongji Medical College of Huazhong University of Science & Technology, Wuhan, 430022, China.
Qing XieShanghai Ruijin Hospital affilated Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Qin NingTongji Hospital Affiliated Tongji Medical College of Huazhong University of Science & Technology, Wuhan, 430030, China.
Hong RenThe Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Huiguo DingBeijing You'an Hospital, Capital Medical University, Fengtai District, Beijing, 100069, China.
Jifang ShengThe First Affiliated Hospital of Zhejiang University Medical College, Hangzhou, 310003, China.
Lai WeiPeking University People's Hospital, Beijing, 100044, China.
Shijun ChenJinan Infectious Disease Hospital, Jinan, 250021, China.
Xiaoling FanCenter of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Wenxiang HuangNo. 1 Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chen PanFuzhou Infectious Disease Hospital, Gulou District, Fuzhou, 350025, China.
Zhiliang GaoThe Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
Jiming ZhangHuashan Hospital, Fudan University, Shanghai, 200040, China.
Boping ZhouShenzhen Donghu Hospital, Shenzhen, 518020, China.
Guofeng ChenBeijing 302 Hospital, Beijing, 100039, China.
Mobin WanShanghai Changhai Hospital, Shanghai, 200433, China.
Hong TangWest China Hospital, Sichuan University, Chengdu, 610041, China.
Guiqiang WangPeking University First Hospital, Beijing, 100034, China.
Yuxiu YangHenan Provincial People's Hospital, Zhengzhou, 450003, China.
Dongping XuBeijing 302 Hospital, Beijing, 100039, China.
Peiling DongBeijing You'an Hospital, Capital Medical University, Fengtai District, Beijing, 100069, China.
Qixin WangMerck, Sharp & Dohme, Shanghai, 200040, China.
Jue WangMerck, Sharp & Dohme, Shanghai, 200040, China.
Fernando A BognarMerck Sharp & Dohme Corp., 600 Corporate Drive, Lebanon, NJ, 08833, USA.
Daozhen XuCenter of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China.
Jun ChengCenter of Hepatology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing, 100015, China. jun.cheng.ditan@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg.

methodsHBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72). The positive predictive value and negative predictive value were calculated for HBsAg alone and/or combined with HBeAg and HBV DNA at weeks 12 and 24.

resultsOf 171 patients included, 58 (33.9 %) achieved a SR. Of patients who achieved a SR, 33 (56.9 %) achieved a CR. Totally 19.3 % (33/171) patients achieved CR and 80.7 % (138/171) patients did not. Patients with HBsAg <1500 IU/mL at week 12 had a 47.4 % chance of achieving an off-treatment SR and patients with a HBsAg decrease >1.5 logIU/mL at week 12 had a 54.5 % chance. Patients with HBsAg >20,000 IU/mL at weeks 12 and 24 had a 93.8 and 100.0 % chance, respectively, of not achieving a CR. An HBsAg level or changes at weeks 12 and 24, combined with HBeAg or HBV DNA, increased the chance for a SR and CR.

conclusionsOn-treatment HBsAg quantification, alone or in combination with HBeAg or HBV DNA, predicted off-treatment SR and CR after 48 weeks of PEG-IFNα-2b therapy, and thus, may guide clinicians in making a therapeutic decision to continue or terminate the therapy.

Indexed as

Decision Support TechniquesAdultAntiviral AgentsAsian PeopleDNA, ViralFemaleHepatitis B, ChronicHepatitis B e AntigensHepatitis B Surface AntigensHumansInterferon-alphaInterferon alpha-2MalePolyethylene GlycolsPredictive Value of TestsRecombinant ProteinsAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaInterferon alpha-2peginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsChronic hepatitis BCombined response (CR)Hepatitis B e antigen (HBeAg)Hepatitis B surface antigen (HBsAg)Peginterferon alfa-2b

Identifiers

PMID27793166
PMCPMC5084370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.